Neurosense Therapeutics Ltd. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

242.65 k

Shareholding (Dec 2024)

FII

0.70%

Held by 6 FIIs

DII

99.23%

Held by 0 DIIs

Promoter

0.00%

How big is Neurosense Therapeutics Ltd.?

22-Jun-2025

As of Jun 18, Neurosense Therapeutics Ltd. has a market capitalization of 57.57 million, with net sales of 0.00 million and a net profit of -10.21 million over the latest four quarters. Shareholder's funds are 2.58 million, and total assets are 4.58 million as of Dec'24.

What does Neurosense Therapeutics Ltd. do?

22-Jun-2025

Neurosense Therapeutics Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $57.57 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -319.32%.

Is Neurosense Therapeutics Ltd. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Neurosense Therapeutics Ltd. shows a mildly bullish technical trend overall, despite mixed signals from weekly indicators and underperformance against the S&P 500, with returns of -3.2% over the past month and -10.37% over the past year.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 29 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.29

Return on Equity

-319.32%

Price to Book

11.05

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2024)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

12.15%

6 Months

-31.03%

1 Year

6.19%

2 Years

-6.98%

3 Years

-28.78%

4 Years

0.0%

5 Years

0.0%

Neurosense Therapeutics Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Neurosense Therapeutics Ltd. technically bullish or bearish?

As of 8 September 2025, the technical trend for Neurosense Therapeutics Ltd. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD is also mildly bullish. However, the weekly MACD and Bollinger Bands are bearish, suggesting mixed signals in the shorter term. The KST shows a bullish monthly trend but is mildly bearish weekly. Overall, the technical stance is mildly bullish, but the strength is tempered by bearish indicators in the weekly timeframe. In terms of performance, the stock has underperformed against the S&P 500 over the past month and year, with returns of -3.2% and -10.37% respectively, compared to the S&P 500's 2.33% and 17.14%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-243.02%

EBIT to Interest (avg)

-8.04

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.29

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.03%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

16.62

EV to EBIT

-4.00

EV to EBITDA

-4.00

EV to Capital Employed

-39.60

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-319.32%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.07%)

Foreign Institutions

Held by 6 Foreign Institutions (0.7%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 40.00% vs 6.25% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "-3.30",
          "chgp": "45.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-3.00",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.99% vs 17.89% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.90",
          "val2": "-12.00",
          "chgp": "17.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.40",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "2.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.20",
          "val2": "-10.10",
          "chgp": "-0.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.80

-3.30

45.45%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.80

-3.00

40.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in quarter ended Dec 2024 is 40.00% vs 6.25% in Dec 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.90

-12.00

17.50%

Interest

0.30

0.40

-25.00%

Exceptional Items

0.00

2.20

-100.00%

Consolidate Net Profit

-10.20

-10.10

-0.99%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -0.99% vs 17.89% in Dec 2023

All Annual Results

Company CV

About Neurosense Therapeutics Ltd.

Neurosense Therapeutics Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Neurosense Therapeutics Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Neurosense Therapeutics Ltd.?

Watch in Real-Time

What does Neurosense Therapeutics Ltd. do?

Is Neurosense Therapeutics Ltd. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Neurosense Therapeutics Ltd. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Neurosense Therapeutics Ltd.

Company Coordinates